These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24100218)

  • 1. What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials?
    Moe SM; Thadhani R
    Curr Opin Nephrol Hypertens; 2013 Nov; 22(6):651-5. PubMed ID: 24100218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
    Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
    Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
    Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
    Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis.
    Parfrey PS; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Chertow GM
    Clin J Am Soc Nephrol; 2016 Mar; 11(3):539-46. PubMed ID: 26614406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study.
    Ketteler M; Martin KJ; Cozzolino M; Goldsmith D; Sharma A; Khan S; Dumas E; Amdahl M; Marx S; Audhya P
    Nephrol Dial Transplant; 2012 May; 27(5):1942-9. PubMed ID: 21931122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
    Sharma A; Marshall TS; Khan SS; Johns B
    Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.
    ; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Goodman WG; Herzog CA; Kubo Y; London GM; Mahaffey KW; Mix TC; Moe SM; Trotman ML; Wheeler DC; Parfrey PS
    N Engl J Med; 2012 Dec; 367(26):2482-94. PubMed ID: 23121374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.
    Ballinger AE; Palmer SC; Nistor I; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2014; 2014(12):CD006254. PubMed ID: 25490118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.
    Wheeler DC; London GM; Parfrey PS; Block GA; Correa-Rotter R; Dehmel B; Drüeke TB; Floege J; Kubo Y; Mahaffey KW; Goodman WG; Moe SM; Trotman ML; Abdalla S; Chertow GM; Herzog CA;
    J Am Heart Assoc; 2014 Nov; 3(6):e001363. PubMed ID: 25404192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.
    Li D; Shao L; Zhou H; Jiang W; Zhang W; Xu Y
    Endocrine; 2013 Feb; 43(1):68-77. PubMed ID: 22669774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study.
    Ketteler M; Martin KJ; Wolf M; Amdahl M; Cozzolino M; Goldsmith D; Sharma A; Marx S; Khan S
    Nephrol Dial Transplant; 2012 Aug; 27(8):3270-8. PubMed ID: 22387567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
    Parfrey PS; Drüeke TB; Block GA; Correa-Rotter R; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Kubo Y; Dehmel B; Goodman WG; Chertow GM;
    Clin J Am Soc Nephrol; 2015 May; 10(5):791-9. PubMed ID: 25710802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial.
    Chertow GM; Correa-Rotter R; Block GA; Drueke TB; Floege J; Goodman WG; Herzog CA; Kubo Y; London GM; Mahaffey KW; Mix TC; Moe SM; Wheeler DC; Parfrey PS
    Nephrol Dial Transplant; 2012 Jul; 27(7):2872-9. PubMed ID: 22529163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
    Joy MS; Karagiannis PC; Peyerl FW
    J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial.
    Moe SM; Abdalla S; Chertow GM; Parfrey PS; Block GA; Correa-Rotter R; Floege J; Herzog CA; London GM; Mahaffey KW; Wheeler DC; Dehmel B; Goodman WG; Drüeke TB;
    J Am Soc Nephrol; 2015 Jun; 26(6):1466-75. PubMed ID: 25505257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
    Bover J; Ureña-Torres P; Lloret MJ; Ruiz C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
    Expert Opin Pharmacother; 2016 Jul; 17(10):1363-73. PubMed ID: 27156578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study.
    Fukagawa M; Fukuma S; Onishi Y; Yamaguchi T; Hasegawa T; Akizawa T; Kurokawa K; Fukuhara S
    Clin J Am Soc Nephrol; 2012 Sep; 7(9):1473-80. PubMed ID: 22822017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease.
    Ritter C; Miller B; Coyne DW; Gupta D; Zheng S; Brown AJ; Slatopolsky E
    Kidney Int; 2017 Nov; 92(5):1217-1222. PubMed ID: 28750928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paricalcitol and cardiorenal outcome: from the IMPACT study to clinical practice.
    Bellasi A; Galassi A; Salvi P; Cozzolino M
    Blood Purif; 2013; 36(1):12-6. PubMed ID: 23736115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of cinacalcet in the treatment of CKD-MBD].
    Koiwa F; Maruta Y
    Clin Calcium; 2010 Jul; 20(7):1089-95. PubMed ID: 20585188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.